-

Thermo Fisher Scientific Introduces the 5L DynaDrive Single-Use Bioreactor to Simplify and Accelerate Process Development and Help Bring Therapies to Market Faster

First-of-its-kind bench scale bioreactor enabling productivity, scalability and efficiency supporting reduced environmental impact

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the 5L DynaDrive Single-Use Bioreactor (S.U.B.), designed to meet the evolving needs of modern bioprocessing. The 5L DynaDrive expands the company's robust portfolio of bioreactors, offering seamless scalability from 1 to 5,000 liters and accelerating bench-scale process development, while facilitating the cost-effective transition from bench to commercialization with consistent reactor design and film across all scales.

"The introduction of the 5L DynaDrive marks a significant advancement in our commitment to helping customers maximize productivity and accelerate time to market," said Ray Mercier, president of Thermo Fisher’s single-use technologies business. "With 25 years of experience in single-use technology, we are dedicated to meeting our customers' evolving needs. Our trusted innovations provide seamless scalability and enhanced efficiency, enabling customers to streamline their bioprocessing workflows and successfully develop and commercialize life-saving therapies."

The 5L DynaDrive single-use bioreactor is engineered to meet the diverse needs of large biopharma, Contract Development and Manufacturing Organizations (CDMOs), and small biotech companies. Its user-friendly design and benchtop size enables use with the HyPerforma™ G3Lab Controller to provide exceptional scalability and scalable proof of concept, affordably. With a 27% increase in productivity compared to glass bioreactors, the 5L DynaDrive combines small size with high performance and offers effective scale-up with consistent design, software, and film across all sizes. The robust, reliable solution utilizes biobased films built on Thermo Fisher’s existing Aegis™ film offerings and BioTitan Retention Devices, enabling minimized product loss and more sustainability.

To learn more about Thermo Fisher’s DynaDrive portfolio, please visit www.thermofisher.com/dynadrive.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact:
Kathy Bricaud
Phone: 442-359-6848
Email: kathy.bricaud@thermofisher.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact:
Kathy Bricaud
Phone: 442-359-6848
Email: kathy.bricaud@thermofisher.com

More News From Thermo Fisher

Thermo Fisher Scientific Launches Applied Biosystems™ PowerFlex™ Thermal Cycler to Advance PCR Flexibility and Productivity

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the Applied Biosystems™ PowerFlex™ Thermal Cycler, a next-generation polymerase chain reaction (PCR) instrument designed to help deliver enhanced flexibility, precise thermal performance and improved productivity for modern molecular biology laboratories. Building on the trusted legacy of Applied Biosystems™ instruments, this solution is designed to help laboratories run complex...

Thermo Fisher Scientific’s PPD Clinical Research Business Collaborates with HealthVerity to Expand Real-World Data Capabilities

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced a strategic data collaboration with HealthVerity, a leading real-world data (RWD) marketplace, to enhance data-driven clinical development and evidence generation for biopharma sponsors. Through the agreement, Thermo Fisher’s PPD™ clinical research business will gain enterprise-level access to HealthVerity’s TaXOnomy® claims dataset, representing more than 270 million de-identified pa...

Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a strategic collaboration with Precision Health Research, Singapore (PRECISE) to advance the PRECISE-SG100K study, one of the region’s most ambitious and diverse population-scale biobank initiatives. The collaboration reflects growing investments from national population studies looking to harness proteomics to drive insight into real-time disease biology for applicat...
Back to Newsroom